These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32431062)

  • 1. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care.
    Tokuyama M; Geisler D; Deitrick C; Fasanella KE; Chennat JS; McGrath KM; Pai RK; Davison JM
    Histopathology; 2020 Sep; 77(3):481-491. PubMed ID: 32431062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
    Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M
    Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
    Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
    Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
    Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
    Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining.
    van der Wel MJ; Duits LC; Pouw RE; Seldenrijk CA; Offerhaus GJA; Visser M; Ten Kate FJ; Biermann K; Brosens LAA; Doukas M; Huysentruyt C; Karrenbeld A; Kats-Ugurlu G; van der Laan JS; van Lijnschoten GI; Moll FCP; Ooms AHAG; van der Valk H; Tijssen JG; Bergman JJ; Meijer SL
    Histopathology; 2018 May; 72(6):1015-1023. PubMed ID: 29314176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
    Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
    Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.
    Younes M; Brown K; Lauwers GY; Ergun G; Meriano F; Schmulen AC; Barroso A; Ertan A
    Histopathology; 2017 Jul; 71(1):27-33. PubMed ID: 28226185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
    Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
    EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.
    Tsoi EH; Williams RA; Christie M; Machet D; Deb S; Sundararajan V; Cameron GR; Desmond PV; Taylor ACF
    Pathology; 2021 Oct; 53(6):700-704. PubMed ID: 34420794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
    Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
    Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.
    den Hoed CM; van Blankenstein M; Dees J; Kuipers EJ
    Br J Cancer; 2011 Jul; 105(2):200-5. PubMed ID: 21673678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
    Redston M; Noffsinger A; Kim A; Akarca FG; Rara M; Stapleton D; Nowden L; Lash R; Bass AJ; Stachler MD
    Gastroenterology; 2022 Feb; 162(2):468-481. PubMed ID: 34757142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.